BioCentury
ARTICLE | Financial News

MeiraGTx proposes $86.3M IPO

May 18, 2018 7:09 PM UTC

MeiraGTx Holdings plc (New York, N.Y.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill Lynch, Barclays, Evercore ISI and Chardan.

The company is developing a portfolio of gene therapies with programs in ophthalmic disease, salivary gland disease and neurodegenerative disorders. The company's AAV-CNGB3, an adeno-associated virus (AAV) vector that delivers the cyclic nucleotide gated channel beta 3 (CNGB3) gene, is in Phase I/II to treat achromatopsia. The candidate has Orphan Drug and rare pediatric disease designations from FDA and Orphan Drug and PRIME designations from EMA in the indication...

BCIQ Company Profiles

MeiraGTx Holdings plc